Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases

Neuro-Oncology

Volumn 18, Issue 10, 2016, Pages 1462-1464

  Kebir, Sied ^a,b,c   Rauschenbach, Laurèl ^a,b   Galldiks, Norbert ^c,d   Schlaak, Max ^c   Hattingen, Elke ^a   Landsberg, Jennifer ^a   Bundschuh, Ralph A ^a   Langen, Karl Josef ^d,e   Scheffler, Björn ^c,f   Herrlinger, Ulrich ^a   Glas, Martin ^a,b,c,g  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Institute of Reconstructive Neurobiology   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d FORSCHUNGSZENTRUM JÜLICH   (Germany)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^f UNIVERSITY HOSPITAL ESSEN   (Germany)

^g MediClin Robert Janker Klinik   (Germany)

Author keywords

brain metastases; FET PET; melanoma; pseudoprogression

Indexed keywords

CHECKPOINT KINASE INHIBITOR; FLUORINE 18; IPILIMUMAB; NIVOLUMAB; O (2 FLUOROETHYL)TYROSINE F 18; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG; RADIOPHARMACEUTICAL AGENT; TYROSINE;

BRAIN METASTASIS; CANCER GROWTH; CLINICAL ARTICLE; HUMAN; LETTER; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; TISSUE METABOLISM; BRAIN TUMOR; DIAGNOSTIC IMAGING; METASTASIS;

BRAIN NEOPLASMS; HUMANS; MELANOMA; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TYROSINE;

EID: 84991287611     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now154     Document Type: Letter

References (5)

1. Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of Immune-Related Response Criteria and RECIST v1. 1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016;34(13):1510-1517.
2. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15(23):7412-7420.
3. Galldiks N, Dunkl V, Stoffels G, et al. Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-Ltyrosine PET. Eur J Nuc Med Mol Imag. 2015;42(5):685-695.
4. Kebir S, Fimmers R, Galldiks N, et al. Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-LTyrosine PET. Clin Cancer Res. 2016;22(9):2190-2196.
5. Bette S, Peschke P, Kaesmacher J, et al. Static FET-PET and MR Imaging in Anaplastic Gliomas (WHO III). World Neurosurg. doi:http://dx. doi. org/10. 1016/j. wneu. 2016. 02. 094.